MAPT and mild neurocognitive disorder: Using novel antibodies to tau phosphorylated at Ser208/210, Thr175 and Thr217, Yang and Strong [36] investigated 5 MND patients with cognitive impairment (ALSci) and 5 others with no cognitive impairment (ALS) (as defined by Strong et al [31]).